Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial

Despite significant progress in the treatment of pediatric acute myeloblastic leukemia (AML), relapse remains the commonest cause of death. Randomized ELAM02 trial questioned if maintenance therapy with interleukin-2 (IL2), for 1 year, improves disease-free survival (DFS). Patients aged 0 to 18 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Petit, Arnaud, Ducassou, Stéphane, Leblanc, Thierry, Pasquet, Marlène, Rousseau, Alexandra, Ragu, Christine, Cachanado, Marine, Nelken, Brigitte, Bertrand, Yves, Michel, Gérard, Gandemer, Virginie, Cuccuini, Wendy, Fenneteau, Odile, Lapillonne, Hélène, Auvrignon, Anne, Baruchel, André, Leverger, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745961/
https://www.ncbi.nlm.nih.gov/pubmed/31723797
http://dx.doi.org/10.1097/HS9.0000000000000159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745961/
https://www.ncbi.nlm.nih.gov/pubmed/31723797
http://dx.doi.org/10.1097/HS9.0000000000000159

Ejemplares similares